Overview
- The FDA approved Lytenava (bevacizumab‑vikg) for neovascular (wet) age‑related macular degeneration, a move announced on July 24, 2026 that makes it the first U.S. ophthalmic bevacizumab product.
- Outlook Therapeutics says the drug is intended for intravitreal use and brings labeled dosing, controlled manufacturing and clinical data to a treatment long supplied off‑label after repackaging.
- The company expects Lytenava to receive 12 years of reference product exclusivity under the Biologics Price Competition and Innovation Act, which could limit biosimilar competition in the U.S.
- Outlook has started U.S. commercial launch activities and plans to make Lytenava available to eligible patients before the end of 2026 while expanding reimbursement and patient support programs.
- The approval closes a multiyear regulatory dispute that included prior FDA rejections and a successful appeal, and Outlook noted standard post‑approval safety monitoring and labeling for intravitreal VEGF inhibitors.